Development and pre-clinical evaluation of G-DSF inhibitors for inflammatory joint disease

G-DSF抑制剂治疗炎症性关节病的开发和临床前评价

• 批准号: nhmrc : 305558
• 负责人: Dr Ian Campbell
• 金额: $ 5.89万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/development-pre-clinical-joint-disease/101379
• 关键词: Development; pre; clinical; evaluation; DSF

G-CSF was originally identified as a cytokine regulating the production of neutrophils and haemopoietic stem cells from the bone marrow and it is currently used clinically for these properties in bone marrow transplant patients around the world. Anti-cytokine therapy with TNF blockade has recently been introduced for the treatment of rheumatoid arthritis. However, not all patients respond to TNF inhibition. We have gathered extensive data which shows that G-CSF also promotes inflammation in experimental models of inflammatory joint disease. We propose to develop inhibitors of G-CSF as a novel form of anti-cytokine therapy for inflammatory joint disorders, such as rheumatoid arthritis.

G-CSF最初被认为是一种调节骨髓中性粒细胞和造血干细胞产生的细胞因子，目前在世界各地的骨髓移植患者中用于临床治疗这些特性。抗细胞因子治疗与TNF阻断最近被引入治疗类风湿关节炎。然而，并非所有患者都对TNF抑制有反应。我们已经收集了大量的数据，表明G-CSF也促进炎症性关节疾病的实验模型中的炎症。我们建议开发G-CSF抑制剂作为抗细胞因子治疗炎症性关节疾病的新形式，如类风湿关节炎。